

Special Issue

Feature Reviews in Tumor Immunology

Message from the Guest Editor

It is now more than five decades since the fields of immunology and oncology were proven to be inextricably linked, overlapping and interacting with each other. From the next generation of hallmarks outlined by Hanahan and Weinberg in *Cell* in 2011 to the successful routine use of immunotherapies and novel immune strategies in clinical trials, advances in the management of human tumors and improvements in the quality of life of patients have been impressive. Unravelling the cellular and molecular pathogenetic mechanisms involved in the tumor microenvironment and the activities of immune cell compartments have paved the way for the development of interventions with monoclonal antibodies, immune checkpoint inhibitors, vaccines, cytokines, immunomodulators and CAR-T cells to prevent or inhibit immune escape and enhance anti-tumor immunity. **This Special Issue welcomes the submission of recent review articles that address immune-related pathogenetic mechanisms, the cellular and molecular networks underlying human tumors, current, novel and future approaches to their exploration, current and future immunotherapeutics, and ongoing pre-clinical and clinical studies on immunotherapies.**

Guest Editor

Dr. Maria-Ioanna Christodoulou

1. Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus

2. School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK

Deadline for manuscript submissions

closed (31 October 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/219749

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).